On Wednesday, Incannex Healthcare Inc ( IXHL ). released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a condition affecting over 900 million people worldwide.

OSA is a common sleep disorder where breathing repeatedly stops and starts during sleep due to a blockage of the upper airway.

The results confirm statistically significant and clinically meaningful improvements across key endpoints.

Also Read: Medicare To Cover Eli Lilly’s Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment

The RePOSA Phase 2 trial demonstrated clear statistically and clinically significant improvements across multiple key endpoints for patients receiving IHL-42X compared to placebo, highlighting its potential to reduce OSA severity and enhance quality of life.

Key Highlights:

Apnoea-Hypopnoea Index (AHI): The low-dose and high-dose IHL-42X groups achieved a statistically significant reduction in percent change in AHI from baseline compared to placebo (p